Table 1.

The variables used in this study, described in more detail in the supplementary file.

Variable Group	Description
demographics	gender, age
subjective clinical data	at baseline (t0)-personal and family medical history-atopy status, allergic rhinitis (AR), atopic dermatitis (AD), food allergy and other comorbidities
objective clinical data	at baseline (t0) and after 6 months (t0 + 6)-symptom control, frequency and severity of exacerbations in the period since the last visit, lung function (FVC, FEV1, MEF50), airway inflammation (FENO) measurement and medication use; at baseline (t0)- skin prick (SPT) and total and specific IgE to inhaled allergens, blood eosinophils and neutrophils, anthropometric measures (height, weight, body mass index) and for certain patients with suggestive history for comorbidities -ENT examination, pH probing with impedance for diagnostics of laryngopharyngeal reflux and gastroesophageal reflux disease, polysomnography for diagnostics of obstructive sleep apnea syndrome, SPT and specific IgE to food and insect venom allergens for diagnostics of food/insect venom allergy
genetic data	genotypes for rs37973 (GLCCI1), rs9910408 (TBX21), rs242941 (CRHR1), rs1876828 (CRHR1), rs1042713 (ADRB2) and rs17576 (MMP9) (see Table S1, Figure S1 and Table S2a,b in the Supplement)

AR: allergic rhinitis, AD: atopic dermatitis, FVC: forced vital capacity, FEV1- forced expiratory volume in one second, MEF50- maximal expiratory flow at 50% of the vital flow capacity, FENO- Fractional Exhaled nitric oxide, SPT: skin prick test, IgE: immunoglobulin E, ENT: ear/nose/throat, GLCCI1: glucocorticoid-induced 1, TBX21: t-box 21, CRHR1: corticotropin releasing hormone receptor 1, ADRB2: beta-2 adrenergic receptor and MMP9: matrix metalloproteinase-9. A full variable list is given in the supplementary file (see Table S3).